Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyridine compound >  Chloropyridine >  oglemilast

oglemilast

Basic information Safety Supplier Related

oglemilast Basic information

Product Name:
oglemilast
Synonyms:
  • GRC 3886
  • oglemilast
  • 4-DifluoroMethoxy-8-MethanesulfonylaMino-dibenzofuran-1-carboxylic acid (3,5-dichloro-pyridin-4-yl)-aMide
  • N-(3,5-Dichloropyridin-4-yl)-4-difluoromethoxy-8-[(methylsulfonyl)amino]dibenzo[b,d]furan-1-carboxamide
  • N-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methylsulfonamido)dibenzo[b,d]furan-1-carboxa
  • N-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methylsulfonamido)dibenzo[b,d]furan-1-carboxamide
  • N-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methylsulfonamido)dibenzo[b,d]furan-1-carb
  • GRC 3886;GRC-3886;GRC3886
CAS:
778576-62-8
MF:
C20H13Cl2F2N3O5S
MW:
516.3
Mol File:
778576-62-8.mol
More
Less

oglemilast Chemical Properties

Density 
1.653
storage temp. 
Store at -20°C
solubility 
DMSO : 4 mg/mL (7.75 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
form 
Powder
pka
7.10±0.30(Predicted)
color 
Light yellow to khaki
More
Less

oglemilast Usage And Synthesis

Uses

Oglemilast (GRC 3886) is a potent and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 0.5 nM for PDE4D3. Oglemilast inhibits pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast has the potential for inflammatory airway diseases[1][2][3].

target

PDE4

IC 50

PDE4D3: .5 nM (IC50)

References

[1] Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking Br J Pharmacol. 2008 Oct;155(3):288-90. DOI:10.1038/bjp.2008.297
[2] Rabe KF, et al. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67. DOI:10.1111/j.1476-5381.2011.01218.x
[3] Wunder F, et al. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter celllines. Mol Pharm. 2013 Oct 7;10(10):3697-705. DOI:10.1021/mp400206m

oglemilastSupplier

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
LETOPHARM LIMITED
Tel
+86-21-5821 5861
Email
sales@letopharm.com
SPIRO PHARMA
Tel
Email
eric_feng1954@126.com